IRWD: The Earnings Call You Can't Afford to Miss! Just My TWO CENTS

Ironwood Pharma (IRWD) is poised for strong earnings due to its Linzess royalty stream with Abbvie, a large cash position, and an upcoming update on its pipeline drug Apraglutide. The author expects a significant earnings beat and a subsequent stock re-rating, arguing that current consensus estimates are far too low. Key catalysts include an update on the strategic review process, the Apraglutide trial results, and expected analyst upgrades. The author also notes significant open interest in call options, suggesting bullish sentiment.